Close

Ultragenyx Pharma (RARE) Begins Phase 3 Study of UX007 in Glut1 DS Patients with Disabling Movement

April 27, 2017 8:39 AM EDT Send to a Friend
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login